test

Stomach and Esophagus

10
A Phase I/II, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
Disease/Condition: Bladder | Breast - Female | Lung | Pancreas | Stomach
Principal Investigator: Joseph Paul Eder
A Phase II Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Disease/Condition: Esophagus | Other Digestive Organ
Principal Investigator: Jeremy Kortmansky
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic Her2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Disease/Condition: Adenocarcinoma of the Gastroesophageal Junction | Esophagus | Gastric Cancer | Stomach
Principal Investigator: Howard Hochster
A Two Part, Phase I, Multi-Center, Open-Label Study of DKN-01 in Combination With Weekly Paclitaxel in Patients With Relapsed or Refractory Esophageal Cancer or Gastro-Esophageal Junction Tumors
Disease/Condition: Esophagus | Other Digestive Organ
Principal Investigator: Stacey Stein
Phase Ib Trial of MPDL3280A with Bevacizumab or with Bevacizumab + FOLFOX in Patients with Solid Tumors
Disease/Condition: Colon | Lung | Rectum
Principal Investigator: Howard Hochster
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Disease/Condition: Esophagus
Principal Investigator: Daniel Boffa